Previous 10 | Next 10 |
The commercial-stage biotech Clovis Oncology (CLVS +9.0%) continues to trade higher on Monday extending the recent rally to third consecutive session following the positive late-stage results announced by the company last week for Rubraca in ovarian cancer. The announcement that the monothera...
Clovis Oncology finally realized some share price upside last week after positive results from a Phase 3 study of its only commercial drug Rubraca. The data suggests Rubraca can enter the 1st line therapy space in Ovarian candidate - the PARP inhibitor extended Progression Free Surviv...
Gainers: Protalix BioTherapeutics (PLX) +70%. Biophytis (BPTS) +21%. Clovis Oncology (CLVS) +13%. IN8bio (INAB) +13%. Acer Therapeutics (ACER) +12%. Losers: Curis (CRIS) -39%. Longeveron (LGVN) -15%. Bioventus (BVS) -14%. Clever Leaves (CLVR) -8%. NanoV...
3 Tips and Tricks for Trading Penny Stocks This Month When you’re thinking about buying penny stocks, it’s important to understand what stocks are, how the stock market works, and what factors are impacting the stock market right now. For starters, penny stocks are sto...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
Thanks to the rise of meme stocks like AMC Entertainment ( NYSE: AMC ) and GameStop ( NYSE: GME ), retail traders are doing more than looking for buy and hold investments. Searching for stocks with high short interest has become commonplace, and for a good reason. In contrast, there...
Clovis Oncology recently reported impressive data from their ATHENA-MONO Phase III study. The ATHENA-MONO data should support the use of Rubraca in the first-line ovarian setting. The company is scheduled to report data from two more Phase III studies for Rubraca this year. Clovis...
Dragged down by a late-day selling spree, Wall Street notched a second consecutive day of losses on Thursday, as investors continued to take profits after the sharp recovery that has marked most of the past few weeks. The slide included a further retreat in homebuilding stocks. From an ...
Shares of Clovis Oncology (NASDAQ: CLVS) jumped 80% this week, according to data from S&P Global Market Intelligence . The stock closed at $1.60 last Friday, then opened on Monday at $1.62. Clovis' big move didn't come until Thursday, however, when the company announced posi...
Gainers: Longeveron (LGVN) +62%. Clovis Oncology (CLVS) +61%. Icosavax (ICVX) +26%. Integrated Media Technology (IMTE) +28%. SAB Biotherapeutics (SABS) +21%. Local Bounti (LOCL) +21%. CPS Technologies (CPSH) +18%. Vector Group (VGR) +17%. Nano-X Imaging (NNOX) +16%. Vertex Energy (VTNR) +16%....
News, Short Squeeze, Breakout and More Instantly...
Receives Commitment for up to $75 Million in Debtor-in-Possession Financing Clovis Oncology, Inc. (NASDAQ:CLVS) (“Clovis” or the Company”), a biopharmaceutical company focused on acquiring, developing, and commercializing innovative anti-cancer agents in the U.S., E...